Bayer AG (FRA:BAYN) has been assigned an average recommendation of “Hold” from the twenty-four brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is €81.67 ($94.97).
BAYN has been the subject of a number of recent research reports. Kepler Capital Markets set a €70.00 ($81.40) target price on Bayer and gave the company a “neutral” rating in a research note on Monday, March 25th. JPMorgan Chase & Co. set a €70.00 ($81.40) target price on Bayer and gave the company a “neutral” rating in a research note on Thursday, March 28th. UBS Group set a €110.00 ($127.91) target price on Bayer and gave the company a “buy” rating in a research note on Thursday, March 28th. Deutsche Bank set a €70.00 ($81.40) target price on Bayer and gave the company a “neutral” rating in a research note on Monday, April 1st. Finally, DZ Bank restated a “neutral” rating on shares of Bayer in a research note on Tuesday, April 2nd.
Shares of BAYN stock traded down €0.31 ($0.36) during trading hours on Friday, reaching €53.90 ($62.67). 3,045,305 shares of the company’s stock were exchanged. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Read More: What does a market perform rating mean?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.